{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T05:17:16Z","timestamp":1790227036268,"version":"4.1.0"},"reference-count":36,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"16","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCO"],"published-print":{"date-parts":[[2002,8,15]]},"abstract":"<jats:p>PURPOSE: The objectives were to determine the maximum-tolerated dose, the recommended dose, the dose-limiting toxicity, the pharmacokinetics, and the activity of E7070, a novel cell-cycle inhibitor.<\/jats:p>\n                  <jats:p>PATIENTS AND METHODS: E7070 was given as a 1-hour intravenous infusion every 3 weeks in two groups of patients with advanced solid tumors who met prespecified eligibility criteria (group A) or who met the same eligibility criteria but in addition were less heavily pretreated and had more favorable liver functions (group B).<\/jats:p>\n                  <jats:p>\n                    RESULTS: Forty patients (31 patients in group A and nine patients in group B) were entered. Dose escalation proceeded through eight levels (range, 50 to 1,000 mg\/m\n                    <jats:sup>2<\/jats:sup>\n                    ). In group A, neutropenia and thrombocytopenia were dose-limiting toxicities occurring during the first cycle in two of seven patients treated at the doses of 700 mg\/m\n                    <jats:sup>2<\/jats:sup>\n                    and two of four patients treated at 800 mg\/m\n                    <jats:sup>2<\/jats:sup>\n                    . Identical dose-limiting toxicities were observed in zero of six and two of three patients from group B at doses of 800 and 1,000 mg\/m\n                    <jats:sup>2<\/jats:sup>\n                    , respectively. Other toxicities included acne-like skin eruption, mucositis, conjunctivitis, nausea, fatigue, and alopecia. At doses greater than 400 mg\/m\n                    <jats:sup>2<\/jats:sup>\n                    , the area under the concentration-time curve increased disproportionately to the administered dose. Tumor stabilization lasting \u2265 6 months was observed in six assessable patients.\n                  <\/jats:p>\n                  <jats:p>\n                    CONCLUSION: The recommended doses of E7070 in this schedule were 700 mg\/m\n                    <jats:sup>2<\/jats:sup>\n                    (group A) and 800 mg\/m\n                    <jats:sup>2<\/jats:sup>\n                    in patients who were less heavily pretreated (group B) with a moderate tumor burden. Prolonged disease stabilization observed in this study might warrant further investigation of E7070 in selected tumor types.\n                  <\/jats:p>","DOI":"10.1200\/jco.2002.09.030","type":"journal-article","created":{"date-parts":[[2002,10,1]],"date-time":"2002-10-01T17:58:26Z","timestamp":1033495106000},"page":"3508-3521","source":"Crossref","is-referenced-by-count":61,"title":["Phase I and Pharmacokinetic Study of E7070, a Novel Chloroindolyl Sulfonamide Cell-Cycle Inhibitor, Administered as a One-Hour Infusion Every Three Weeks in Patients With Advanced Cancer"],"prefix":"10.1200","volume":"20","author":[{"given":"E.","family":"Raymond","sequence":"first","affiliation":[{"name":"From the Institut Gustave-Roussy, Villejuif, France; Netherlands Cancer Institute and NDDO Oncology, Amsterdam, the Netherlands; and Eisai Limited, London, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W.W.","family":"ten Bokkel Huinink","sequence":"additional","affiliation":[{"name":"From the Institut Gustave-Roussy, Villejuif, France; Netherlands Cancer Institute and NDDO Oncology, Amsterdam, the Netherlands; and Eisai Limited, London, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Ta\u00efeb","sequence":"additional","affiliation":[{"name":"From the Institut Gustave-Roussy, Villejuif, France; Netherlands Cancer Institute and NDDO Oncology, Amsterdam, the Netherlands; and Eisai Limited, London, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.H.","family":"Beijnen","sequence":"additional","affiliation":[{"name":"From the Institut Gustave-Roussy, Villejuif, France; Netherlands Cancer Institute and NDDO Oncology, Amsterdam, the Netherlands; and Eisai Limited, London, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Faivre","sequence":"additional","affiliation":[{"name":"From the Institut Gustave-Roussy, Villejuif, France; Netherlands Cancer Institute and NDDO Oncology, Amsterdam, the Netherlands; and Eisai Limited, London, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Wanders","sequence":"additional","affiliation":[{"name":"From the Institut Gustave-Roussy, Villejuif, France; Netherlands Cancer Institute and NDDO Oncology, Amsterdam, the Netherlands; and Eisai Limited, London, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Ravic","sequence":"additional","affiliation":[{"name":"From the Institut Gustave-Roussy, Villejuif, France; Netherlands Cancer Institute and NDDO Oncology, Amsterdam, the Netherlands; and Eisai Limited, London, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Fumoleau","sequence":"additional","affiliation":[{"name":"From the Institut Gustave-Roussy, Villejuif, France; Netherlands Cancer Institute and NDDO Oncology, Amsterdam, the Netherlands; and Eisai Limited, London, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.P.","family":"Armand","sequence":"additional","affiliation":[{"name":"From the Institut Gustave-Roussy, Villejuif, France; Netherlands Cancer Institute and NDDO Oncology, Amsterdam, the Netherlands; and Eisai Limited, London, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.H.M.","family":"Schellens","sequence":"additional","affiliation":[{"name":"From the Institut Gustave-Roussy, Villejuif, France; Netherlands Cancer Institute and NDDO Oncology, Amsterdam, the Netherlands; and Eisai Limited, London, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"233","reference":[{"key":"R1-113579","doi-asserted-by":"publisher","DOI":"10.1126\/science.274.5293.1672"},{"key":"R2-113579","unstructured":"Sherr  CJ:   The Pezcoller lecture:  Cancer cell cycles revisited.   Cancer Res 60:  3689,2000-3695,"},{"key":"R3-113579","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/92.5.376"},{"key":"R4-113579","doi-asserted-by":"publisher","DOI":"10.1016\/S0163-7258(98)00062-X"},{"key":"R5-113579","doi-asserted-by":"crossref","unstructured":"Meijer  L:   Chemical inhibitors of cyclin-dependent kinases.  Prog Cell Cycle Res 1:  351,1995-363,","DOI":"10.1007\/978-1-4615-1809-9_29"},{"key":"R6-113579","doi-asserted-by":"publisher","DOI":"10.1016\/S0163-7258(98)00057-6"},{"key":"R7-113579","doi-asserted-by":"publisher","DOI":"10.1517\/13543784.9.8.1849"},{"key":"R8-113579","unstructured":"Owa  T,   Yoshino  H,   Okauchi  T,  et al:  A novel antitumor agent ER-35744, targeting G1 phase I:  Discovery and structure-activity relationships.   Proc Am Assoc Cancer Res 37:  A2664,1996  (abstr)"},{"key":"R9-113579","unstructured":"Owa  T,   Yokoi  A,   Kuromitsu  J,  et al:  Microarray based expression profiling of sulfonamide antitumor agents.  Proc Am Assoc Cancer Res 42:  371,2001  (abstr A1998)"},{"key":"R10-113579","unstructured":"Watanabe  T,   Sugi  NH,   Ozawa  Y,  et al:  A novel antitumor agent ER-35744, targeting G1 phase III:  Studies of mechanism of action.   Proc Am Assoc Cancer Res 37:  A2667,1996  (abstr)"},{"key":"R11-113579","unstructured":"Ozawa  Y,   Funahashi  Y,   Senba  T,  et al:  Antitumor effects of E7070 (ER-35744) against orthotopically transplanted mouse and human colorectal tumors.  Proc Am Assoc Cancer Res 38:  A3163,1997  (abstr)"},{"key":"R12-113579","unstructured":"Sugi  NH,   Ozawa  Y,   Watanabe  T,  et al:  A novel agent ER-35744, targeting G1 phase II:  Antitumor activities in vitro and in vivo.   Proc Am Assoc Cancer Res 37:  A2668,1996  (abstr)"},{"key":"R13-113579","unstructured":"Monks  A,   Scudiero  DA,   Johnson  GS,  et al:  The NCI anti-cancer drug screen:  A smart screen to identify effectors of novel targets.   Anticancer Drug Des 12:  533,1997-541,"},{"key":"R14-113579","doi-asserted-by":"publisher","DOI":"10.1016\/0006-2952(89)90123-8"},{"key":"R15-113579","doi-asserted-by":"publisher","DOI":"10.1007\/BF00873904"},{"key":"R16-113579","doi-asserted-by":"publisher","DOI":"10.1007\/BF00686832"},{"key":"R17-113579","unstructured":"Rigas  JR,   Tong  WP,   Kris  MG,  et al:  Phase I clinical and pharmacological study of chloroquinoxaline sulfonamide.  Cancer Res 52:  6619,1992-6623,"},{"key":"R18-113579","doi-asserted-by":"publisher","DOI":"10.1016\/0006-2952(88)90672-7"},{"key":"R20-113579","doi-asserted-by":"publisher","DOI":"10.1101\/gad.13.12.1501"},{"key":"R21-113579","doi-asserted-by":"publisher","DOI":"10.1517\/13543784.9.12.2903"},{"key":"R22-113579","doi-asserted-by":"publisher","DOI":"10.1023\/A:1006353008903"},{"key":"R23-113579","unstructured":"Innocenti  F,   Stadler  WM,   Iyer  L,  et al:  Flavopiridol metabolism in cancer patients is associated with the occurrence of diarrhea.  Clin Cancer Res 6:  3400,2000-3405,"},{"key":"R24-113579","unstructured":"Kahn  ME,   Senderowicz  A,   Sausville  EA,  et al:  Possible mechanisms of diarrheal side effects associated with the use of a novel chemotherapeutic agent, flavopiridol.  Clin Cancer Res 7:  343,2001-349,"},{"key":"R25-113579","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2001.19.7.1985"},{"key":"R26-113579","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1998.16.9.2986"},{"key":"R27-113579","unstructured":"Shapiro  GI,   Supko  JG,   Patterson  A,  et al:  A phase II trial of the cyclin-dependent kinase inhibitor flavopiridol in patients with previously untreated stage IV non-small cell lung cancer.  Clin Cancer Res 7:  1590,2001-1599,"},{"key":"R28-113579","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2000.18.2.371"},{"key":"R29-113579","unstructured":"Fuse  E,   Tanii  H,   Kurata  N,  et al:  Unpredicted clinical pharmacology of UCN-01 caused by specific binding to human alpha1-acid glycoprotein.  Cancer Res 58:  3248,1998-3253,"},{"key":"R30-113579","doi-asserted-by":"publisher","DOI":"10.1007\/s002800051080"},{"key":"R31-113579","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/88.14.956"},{"key":"R32-113579","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2001.19.8.2319"},{"key":"R33-113579","doi-asserted-by":"publisher","DOI":"10.1021\/jm9902638"},{"key":"R34-113579","doi-asserted-by":"publisher","DOI":"10.2174\/0929867013371996"},{"key":"R35-113579","doi-asserted-by":"publisher","DOI":"10.1023\/A:1010608317361"},{"key":"R36-113579","doi-asserted-by":"publisher","DOI":"10.1023\/A:1012287111922"},{"key":"R37-113579","doi-asserted-by":"crossref","unstructured":"Ozawa  Y,   Sugi  NH,   Nagasu  T,  et al:  E7070, a novel sulphonamide agent with potent antitumour activity in vitro and in vivo.  Eur J Cancer 3:  2275,2001-2282,","DOI":"10.1016\/S0959-8049(01)00275-1"}],"container-title":["Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/JCO.2002.09.030","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,25]],"date-time":"2022-05-25T17:52:22Z","timestamp":1653501142000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/JCO.2002.09.030"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,8,15]]},"references-count":36,"journal-issue":{"issue":"16","published-print":{"date-parts":[[2002,8,15]]}},"alternative-id":["10.1200\/JCO.2002.09.030"],"URL":"https:\/\/doi.org\/10.1200\/jco.2002.09.030","relation":{},"ISSN":["0732-183X","1527-7755"],"issn-type":[{"value":"0732-183X","type":"print"},{"value":"1527-7755","type":"electronic"}],"subject":[],"published":{"date-parts":[[2002,8,15]]}}}